AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

Milk Volume Outcomes Following Oral Nicotinamide Riboside Supplementation in Mothers of Extremely Preterm Infants

RecruitingPhase 2, Phase 3Ages 18 Years - anyFemaleUniversity of California, Davis
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

This study aims to evaluate the feasibility and effects of nicotinamide riboside (NR) supplementation in lactating mothers of infants expected to be hospitalized in the neonatal intensive care unit (NICU) for at least four weeks.

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion criteria are required to be met before or at enrollment: Mothers who are 18 years or older. Infants delivered at 24-32 weeks OR infants (any GA) that researchers anticipate will be hospitalized in the NICU for at least 4 weeks, including, but not limited to, infants with a diagnosis of gastroschisis, a cardiac defect, intestinal atresia, etc. Infants born at the UC Davis Medical Center or transferred to the UC Davis Medical Center NICU within the first 7 days of life. Mothers who attempted initial milk expression within 12 hours of delivery. Mothers who attempted milk expression at least 6 times every 24 hours from 72 hours after delivery to the Enrollment Visit. Mothers who have delivered at least 96 hours (4 days) prior to the Enrollment Visit. Mothers who have experienced a level "3" on the OMPQ before starting the collection of their first 24-hour pooled milk sample (study days 0-3). Mothers who plan to feed their infants breast milk for at least 3 months. Mothers who were pregnant with one infant. Mothers willing to refrain from tandem feeding (directly breastfeeding) another child during the study period. Mothers willing to refrain from enrolling themselves in another intervention trial during the study period. Mothers willing to express, weigh, record, and collect 24-hour pooled milk Mothers willing to remove nipple piercings during the study period. Mothers willing to refrain from using pseudoephedrine (often found in Sudafed, Theraflu, Claritin-D, etc.) during the study period. Mothers willing to express milk 6 times or more every 24 hours, including at least once during the night, and with no more than 5 hours between milk expression sessions, during the study period. Mothers willing to refrain from consuming non-study supplements that contain nicotinamide-riboside (or similar derivatives, including NMN) during the study period. Mothers willing to refrain from consuming galactagogues during the study period.
๐Ÿ’Š

What it tests

  • Nicotinamide Riboside (NR)
  • Placebo
๐Ÿ“

Where

1 site
University of California, Davis
Sacramento, United States
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy